Literature DB >> 2404502

Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.

E Blychert1, K Wingstrand, B Edgar, K Lidman.   

Abstract

1. The rate and extent of felodipine absorption from an oral solution, conventional and extended-release tablets were investigated in two groups of healthy volunteers (n = 18 + 15). 2. The antihypertensive effect of felodipine conventional tablets twice daily (n = 71) and extended-release tablets once daily (n = 76) were compared in a parallel-group study in hypertensive patients. 3. As from a solution, felodipine was completely absorbed from the two solid dosage forms. The rate of absorption increased in the order extended-release tablets, conventional tablets, solution. 4. The extended-release tablet gave more sustained plasma concentrations than the conventional tablet. 5. The extended-release tablet given once daily gave similar blood pressure control to the conventional tablet given twice daily.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2404502      PMCID： PMC1380059          DOI： 10.1111/j.1365-2125.1990.tb03600.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  7 in total

1.  Dissolution test for felodipine tablets using chemical oxidation in situ to maintain 'sink conditions'.

Authors:  K Felle; B Persson; J Vessman
Journal:  J Pharm Biomed Anal       Date:  1984       Impact factor: 3.935

2.  Comparison of high-selectivity gas chromatographic methods, including column switching, for the determination of felodipine in plasma.

Authors:  M Ahnoff; M Ervik; L Johansson
Journal:  J Chromatogr       Date:  1987-05-29

3.  Treatment of essential hypertension with felodipine in combination with a diuretic.

Authors:  T Hedner; O Samuelsson; E Sjögren; D Elmfeldt
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of felodipine. A summary.

Authors:  B Edgar; P Lundborg; C G Regårdh
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Determination of felodipine in plasma by capillary gas chromatography with electron capture detection.

Authors:  M Ahnoff
Journal:  J Pharm Biomed Anal       Date:  1984       Impact factor: 3.935

6.  Felodipine kinetics in healthy men.

Authors:  B Edgar; C G Regårdh; G Johnsson; L Johansson; P Lundborg; I Löfberg; O Rönn
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

7.  Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses.

Authors:  B Edgar; C G Regårdh; P Lundborg; S Romare; G Nyberg; O Rönn
Journal:  Biopharm Drug Dispos       Date:  1987 May-Jun       Impact factor: 1.627
  7 in total
  10 in total

1.  Drug delivery systems for treatment of systemic hypertension.

Authors:  L Michael Prisant; William J Elliott
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Twenty-four hour blood pressure profiles in hypertensive patients following various formulations and dosage regimens of felodipine.

Authors:  E Blychert; M Frisén; O Karlsson; L Rydén
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Augmented bioavailability of felodipine through an α-linolenic acid-based microemulsion.

Authors:  Mahendra Singh; Jovita Kanoujia; Poonam Parashar; Malti Arya; Chandra B Tripathi; V R Sinha; Shailendra K Saraf; Shubhini A Saraf
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

4.  Clinical equivalence of two tablet formulations of felodipine. A placebo-controlled study of 24-hour blood pressure control and tolerability.

Authors:  B P McGrath; R W Watts; D B Elmfeldt
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 5.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

6.  Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets.

Authors:  B Abrahamsson; M Alpsten; M Hugosson; U E Jonsson; M Sundgren; A Svenheden; J Tölli
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

Review 7.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

8.  Evaluation of solubilizers in the drug release testing of hydrophilic matrix extended-release tablets of felodipine.

Authors:  B Abrahamsson; D Johansson; A Torstensson; K Wingstrand
Journal:  Pharm Res       Date:  1994-08       Impact factor: 4.200

9.  A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug-Drug Interaction Modeling.

Authors:  Laura Maria Fuhr; Fatima Zahra Marok; Maximilian Mees; Felix Mahfoud; Dominik Selzer; Thorsten Lehr
Journal:  Pharmaceutics       Date:  2022-07-15       Impact factor: 6.525

10.  Formulation, Optimization, In Vitro and In Vivo Evaluation of Saxagliptin-Loaded Lipospheres for an Improved Pharmacokinetic Behavior.

Authors:  Akhtar Rasul; Safirah Maheen; Hafeez Ullah Khan; Maria Rasool; Shahid Shah; Ghulam Abbas; Khurram Afzal; Fatima Tariq; Irum Shahzadi; Muhammad Hassham Hassan Bin Asad
Journal:  Biomed Res Int       Date:  2021-10-20       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.